GATC Biotech Orders Europe’s First HiSeq 2000 for Commercial Use
News Jan 22, 2010
GATC Biotech has announced the purchase of Illumina’s new HiSeq 2000 sequencing platform, which has officially been launched last week. This latest acquisition will further strengthen GATC Biotech’s current fleet of three GA IIx.
Initially, the company will employ the HiSeq 2000 to human genome sequencing projects from its customers in the pharmaceutical and medical research field. It will also make the system’s high data output available to the industrial and academic research community interested in the high throughput sequencing of larger eukaryotic genomes.
“Illumina’s HiSeq 2000 with the estimated output of 200 GB per run allows us to virtually sequence 60 human genomes at 1x coverage in a week. Being an Illumina CSPro certified service provider we are confident to have the system quickly installed and geared up for production,” says Peter Pohl, CEO of GATC Biotech.
The HiSeq 2000 sequencing system had just been launched by llumina Inc. on the occasion of the J.P. Morgan Healthcare Conference last week in San Diego.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Algorithm Speeds Up Medical Image Analysis 1000 TimesNews
Medical image registration is a common technique that involves overlaying two images, such as magnetic resonance imaging (MRI) scans, to compare and analyze anatomical differences in great detail. Researchers have described a machine-learning algorithm that can register brain scans and other 3-D images more than 1,000 times more quickly using novel learning techniques.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.